UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment

(UroToday.com) The 2024 IBCN annual meeting included a session on treatment response correlates, featuring a presentation by Dr. Trine Strandgaard discussing spatial proteomics and transcriptomics in ...
UroToday

EAU 2022: State of the Art Lecture: Synchronous vs Metachronous mHSPC: What makes the difference?

(UroToday.com) The 37 th Annual European Association of Urology Congress held in Amsterdam, the Netherlands between July 1 st, and 4 th 2022 was host to a session about the management of metastatic ...
UroToday

ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a presidential symposium. Dr. Jun Guo presented the results of a trial of disitamab vedotin + ...
UroToday

ASCO GU 2026: Discussant: Improving Outcomes for Radiotherapy

(UroToday.com) The 2026 GU ASCO annual meeting featured a prostate cancer session and a discussant presentation by Dr. Bridget Koontz, discussing two abstracts, “Hormone therapy use and duration with ...